Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICAM: Phase II Trial of Nilotinib in c-KIT Mutated Advanced Acral and Mucosal Melanoma
2009-012945-49Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in acral lentiginous melanoma (ALM), mucosal melanoma (MM) and Malignant melanoma of other specified sites (MM), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: 6-month progression-free survival proportion. Started Sep 2009; status: completed.
02
Drugs
nilotinib
03
Conditions
acral lentiginous melanoma (ALM)mucosal melanoma (MM)Malignant melanoma of other specified sites (MM)
Beyond the preview
Go deeper on 2009-012945-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012945-49.